MARKET

RNXT

RNXT

Renovorx Inc
NASDAQ
0.8636
-0.0165
-1.87%
After Hours: 0.9116 +0.048 +5.56% 17:05 05/08 EDT
OPEN
0.9116
PREV CLOSE
0.8801
HIGH
0.9116
LOW
0.8545
VOLUME
311.91K
TURNOVER
--
52 WEEK HIGH
1.450
52 WEEK LOW
0.7006
MARKET CAP
38.91M
P/E (TTM)
-2.7320
1D
5D
1M
3M
1Y
5Y
1D
RenovoRx forecasts 2026 revenue of $3 million-$4 million
PUBT · 4d ago
Weekly Report: what happened at RNXT last week (0427-0501)?
Weekly Report · 4d ago
RenovoRx to host first-quarter financial results conference call
PUBT · 04/29 12:31
Press Release: RenovoRx to Host First Quarter -2-
Dow Jones · 04/29 12:30
Press Release: RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
Dow Jones · 04/29 12:30
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA)
TipRanks · 04/28 18:50
Weekly Report: what happened at RNXT last week (0420-0424)?
Weekly Report · 04/27 10:39
RenovoRx ASCO abstract reports PK/PD data from Phase III TIGeR-PaC trial
PUBT · 04/23 12:32
More
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Webull offers RenovoRx Inc stock information, including NASDAQ: RNXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNXT stock methods without spending real money on the virtual paper trading platform.